| 690- | EGCG, | Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer |
| - | in-vitro, | Pca, | NA |
| 689- | EGCG, | EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9 |
| - | vitro+vivo, | Bladder, | SW780 |
| - | in-vitro, | PC, | NA |
| 687- | EGCG, | Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 686- | EGCG, | Prevention effect of EGCG in rat's lung cancer induced by benzopyrene |
| - | in-vivo, | Lung, | NA |
| 685- | EGCG, | CUR, | SFN, | RES, | GEN | The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein |
| - | Analysis, | NA, | NA |
| 683- | EGCG, | Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy |
| - | Review, | NA, | NA |
| 684- | EGCG, | Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation |
| - | in-vitro, | CRC, | NA |
| 675- | EGCG, | When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy |
| - | Review, | Var, | NA |
| 676- | EGCG, | Chemo, | The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review |
| - | Review, | NA, | NA |
| 677- | EGCG, | Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α |
| - | in-vitro, | CRC, | HT-29 |
| 678- | EGCG, | Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells |
| 679- | EGCG, | 5-FU, | Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer |
| - | in-vitro, | CRC, | NA |
| 680- | EGCG, | Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea |
| - | Review, | NA, | NA |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 682- | EGCG, | Suppressive Effects of EGCG on Cervical Cancer |
| - | Review, | NA, | NA |
| 2395- | EGCG, | EGCG inhibits diabetic nephrophathy through up regulation of PKM2 |
| - | Study, | Diabetic, | NA |
| 2302- | EGCG, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2309- | EGCG, | Chemo, | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 2310- | EGCG, | Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells |
| - | in-vitro, | lymphoma, | PEL |
| 2994- | EGCG, | Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy |
| - | Review, | Var, | NA |
| 2993- | EGCG, | Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 2992- | EGCG, | Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity |
| - | Review, | Var, | NA |
| - | Trial, | NA, | NA |
| 2501- | EGCG, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 2458- | EGCG, | QC, | Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies |
| - | Analysis, | Nor, | NA |
| 2459- | EGCG, | Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis |
| - | in-vitro, | Tong, | Tca8113 | - | in-vitro, | Tong, | TSCCa |
| - | in-vitro, | Nor, | HSC-T6 |
| 2563- | EGCG, | Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies |
| - | Review, | NA, | NA |
| 2468- | EGCG, | Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists |
| - | in-vitro, | Nor, | NA |
| 2561- | EGCG, | ASA, | Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment |
| - | ex-vivo, | Nor, | NA |
| 4680- | EGCG, | The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review |
| - | Review, | Var, | NA |
| 4684- | EGCG, | EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells |
| - | in-vivo, | NSCLC, | A549 |
| 4681- | EGCG, | Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling |
| - | in-vitro, | Ovarian, | ES-2 |
| 4682- | EGCG, | Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate |
| - | Review, | Var, | NA |
| 4683- | EGCG, | Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 4685- | EGCG, | Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines |
| - | in-vitro, | NPC, | TW01 | - | in-vitro, | NPC, | TW06 |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| 4291- | EGCG, | Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro |
| - | in-vitro, | AD, | NA |
| 1975- | EGCG, | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
| - | in-vitro, | Cerv, | HeLa |
| 1974- | EGCG, | Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes |
| - | in-vitro, | Nor, | NA |
| - | in-vitro, | GBM, | U87MG |
| 1303- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
| - | in-vitro, | EC, | NA |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1503- | EGCG, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 1515- | EGCG, | Phen, | Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | BT20 |
| 3428- | EGCG, | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
| - | Review, | Var, | NA |
| 3230- | EGCG, | Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 3229- | EGCG, | Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells |
| - | in-vitro, | Nor, | HMEC | - | in-vitro, | Nor, | HUVECs |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid